Latest Breaking News On - Enhanced delivery oligonucleotide - Page 1 : comparemela.com

PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights

PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
marketscreener.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from marketscreener.com Daily Mail and Mail on Sunday newspapers.

United statesUnited kingdomJames mcarthurSarah suttonNoel donnellyPepgen incDrug administrationRegulatory agencyInternational myotonic dystrophy consortiumMuscular dystrophy associationDuchenne muscular dystrophyEnhanced delivery oligonucleotideRare pediatric disease designationsOrphan drugDystrophy associationRepeat dose nonclinical data

PepGen Receives U S FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

BOSTON, March 13, 2024 PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe.

United statesJames mcarthurLaurence wattsSarah suttonPepgen incDrug administrationGilmartin groupOrphan drug actRare pediatric diseaseOrphan drugEnhanced delivery oligonucleotideDuchenne muscular dystrophyPrivate securities litigation reform act

PepGen Receives U S FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for

BOSTON, March 13, 2024 (GLOBE NEWSWIRE) PepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of

United statesLaurence wattsSarah suttonJames mcarthurPepgen incGilmartin groupDrug administrationOrphan drug actRare pediatric diseaseOrphan drugEnhanced delivery oligonucleotideDuchenne muscular dystrophyPrivate securities litigation reform act

PepGen Announces Pricing of $80 1 Million Underwritten Offering of Common Stock

BOSTON, Feb. 07, 2024 PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe.

United statesSarah suttonLaurence wattsPepgen incExchange commissionSyndicate departmentLeerink partnersFrazier life sciencesGilmartin groupJanus henderson investorsLaurion capital managementMonashee investment managementOctagon capitalPerceptive advisorsEnhanced delivery oligonucleotide

Mary Beth DeLena Joins PepGen as General Counsel and Secretary

BOSTON, Jan. 17, 2024 PepGen Inc. , a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe.

United statesMary beth delenaMary bethLaurence wattsJames mcarthurSarah suttonPraecis pharmaceuticalsPepgen incTrinity collegeAlnylam pharmaceuticalsMeagher flomGilmartin groupNortheastern university school of lawGeneral counselSenior vice presidentDeputy general counsel